EdgeScore

VBIO · Nasdaq

Valion Bio, Inc.: financial statements

Financially weak · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2021: $1.3MNet income 2021: -$8.5M2021Revenue 2022: $1.8MNet income 2022: -$10.1M2022Revenue 2023: $1.2MNet income 2023: -$8.2M2023Revenue 2024: $780KNet income 2024: -$5.7M2024
RevenueNet income

Operating and free cash flow

Operating cash flow 2021: -$5.6MFree cash flow 2021: -$5.6M2021Operating cash flow 2022: -$8.9MFree cash flow 2022: -$8.9M2022Operating cash flow 2023: -$8.5MFree cash flow 2023: -$8.6M2023Operating cash flow 2024: -$5.7MFree cash flow 2024: -$5.7M2024
Operating cash flowFree cash flow

Margins

Gross 2021: -3.0%Gross 2022: 16.3%Gross 2023: 24.4%Gross 2024: 0.3%Operating 2021: -448.1%Operating 2022: -548.8%Operating 2023: -701.1%Operating 2024: -573.8%Net 2021: -675.7%Net 2022: -548.7%Net 2023: -701.0%Net 2024: -725.0%2021202220232024
GrossOperatingNet

Returns

ROE 2021: -64.0%ROE 2022: -278.1%ROE 2023: -230.3%ROE 2024: -223.1%ROIC 2021: -1498.3%ROIC 2022: -3891.4%ROIC 2023: -4371.5%ROIC 2024: -1246.8%ROA 2021: -56.5%ROA 2022: -171.8%ROA 2023: -159.9%ROA 2024: -201.5%2021202220232024
ROEROICROA

Income statement

USD2021202220232024Last year
Revenue$1.3M$1.8M$1.2M$780K-34%
Gross profit-$38.0K$299K$287K$2.0K-99%
Selling, general & admin$4.7M$8.7M$6.9M$3.2M-54%
Operating income-$5.6M-$10.1M-$8.2M-$4.5M+46%
EBITDA-$5.6M-$10.1M-$8.2M-$4.5M+46%
Interest expense———$0
Profit before tax—-$10.1M-$8.2M$5.7M+169%
Income tax———$0
Net income-$8.5M-$10.1M-$8.2M-$5.7M+31%

Cash flow

USD2021202220232024Last year
Operating cash flow-$5.6M-$8.9M-$8.5M-$5.7M+33%
Capital expenditure—$11.0K$118K$0-100%
Free cash flow-$5.6M-$8.9M-$8.6M-$5.7M+34%
Depreciation & amortization$8.0K$10.0K$8.0K$3.0K-63%

Balance sheet

USD2021202220232024Last year
Cash$13.0M$3.5M$3.4M$2.0M-41%
Inventory$429K$863K$756K$319K-58%
Current assets$14.3M$5.3M$4.7M$2.6M-43%
Total assets$15.0M$5.9M$5.2M$2.8M-46%
Current liabilities$1.2M$1.9M$1.4M$272K-81%
Total liabilities$1.8M$2.2M$1.6M$272K-83%
Shareholders' equity$13.3M$3.6M$3.6M$2.5M-29%
Net debt-$13.0M-$3.5M-$3.4M-$2.0M+41%

Ratios

2021202220232024Last year
Gross margin-3.0%16.3%24.4%0.3%
Operating margin-448.1%-548.8%-701.1%-573.8%
Net margin-675.7%-548.7%-701.0%-725.0%
SG&A as share of revenue375.3%471.0%584.8%405.5%
Return on equity-64.0%-278.1%-230.3%-223.1%
Return on assets-56.5%-171.8%-159.9%-201.5%
Return on invested capital-1498.3%-3891.4%-4371.5%-1246.8%
Current ratio11.722.833.329.70
Quick ratio11.372.372.788.53

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.